These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 34330748)

  • 21. Group II metabotropic glutamate receptor activation by agonist LY379268 treatment increases the expression of brain derived neurotrophic factor in the mouse brain.
    Di Liberto V; Bonomo A; Frinchi M; Belluardo N; Mudò G
    Neuroscience; 2010 Feb; 165(3):863-73. PubMed ID: 19909793
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Activation of mGlu3 metabotropic glutamate receptors enhances GDNF and GLT-1 formation in the spinal cord and rescues motor neurons in the SOD-1 mouse model of amyotrophic lateral sclerosis.
    Battaglia G; Riozzi B; Bucci D; Di Menna L; Molinaro G; Pallottino S; Nicoletti F; Bruno V
    Neurobiol Dis; 2015 Feb; 74():126-36. PubMed ID: 25434487
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The metabotropic glutamate 2/3 receptor agonists LY354740 and LY379268 selectively attenuate phencyclidine versus d-amphetamine motor behaviors in rats.
    Cartmell J; Monn JA; Schoepp DD
    J Pharmacol Exp Ther; 1999 Oct; 291(1):161-70. PubMed ID: 10490900
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The mGluR5 positive allosteric modulator, CDPPB, ameliorates pathology and phenotypic signs of a mouse model of Huntington's disease.
    Doria JG; de Souza JM; Andrade JN; Rodrigues HA; Guimaraes IM; Carvalho TG; Guatimosim C; Dobransky T; Ribeiro FM
    Neurobiol Dis; 2015 Jan; 73():163-73. PubMed ID: 25160573
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The mGluR2/3 agonist LY379268 reverses post-weaning social isolation-induced recognition memory deficits in the rat.
    Jones CA; Brown AM; Auer DP; Fone KC
    Psychopharmacology (Berl); 2011 Mar; 214(1):269-83. PubMed ID: 20607219
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cognitive deficits in transgenic and knock-in HTT mice parallel those in Huntington's disease.
    Farrar AM; Murphy CA; Paterson NE; Oakeshott S; He D; Alosio W; McConnell K; Menalled LB; Ramboz S; Park LC; Howland D; Brunner D
    J Huntingtons Dis; 2014; 3(2):145-58. PubMed ID: 25062858
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization of neurophysiological and behavioral changes, MRI brain volumetry and 1H MRS in zQ175 knock-in mouse model of Huntington's disease.
    Heikkinen T; Lehtimäki K; Vartiainen N; Puoliväli J; Hendricks SJ; Glaser JR; Bradaia A; Wadel K; Touller C; Kontkanen O; Yrjänheikki JM; Buisson B; Howland D; Beaumont V; Munoz-Sanjuan I; Park LC
    PLoS One; 2012; 7(12):e50717. PubMed ID: 23284644
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Metabotropic glutamate receptor 5 knockout promotes motor and biochemical alterations in a mouse model of Huntington's disease.
    Ribeiro FM; Devries RA; Hamilton A; Guimaraes IM; Cregan SP; Pires RG; Ferguson SS
    Hum Mol Genet; 2014 Apr; 23(8):2030-42. PubMed ID: 24282028
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The preclinical properties of a novel group II metabotropic glutamate receptor agonist LY379268.
    Imre G
    CNS Drug Rev; 2007; 13(4):444-64. PubMed ID: 18078428
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The metabotropic glutamate 2/3 receptor agonist LY379268 counteracted ketamine-and apomorphine-induced performance deficits in the object recognition task, but not object location task, in rats.
    Pitsikas N; Markou A
    Neuropharmacology; 2014 Oct; 85():27-35. PubMed ID: 24859609
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Small Molecule Pytren-4QMn Metal Complex Slows down Huntington's Disease Progression in Male zQ175 Transgenic Mice.
    Merino M; González S; Tronch MC; Sánchez-Sánchez AV; Clares MP; García-España A; García-España E; Mullor JL
    Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894844
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Activation of group II metabotropic glutamate receptors induces long-term depression of excitatory synaptic transmission in the substantia nigra pars reticulata.
    Johnson KA; Niswender CM; Conn PJ; Xiang Z
    Neurosci Lett; 2011 Oct; 504(2):102-106. PubMed ID: 21945652
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Behavioral and functional evidence of metabotropic glutamate receptor 2/3 and metabotropic glutamate receptor 5 dysregulation in cocaine-escalated rats: factor in the transition to dependence.
    Hao Y; Martin-Fardon R; Weiss F
    Biol Psychiatry; 2010 Aug; 68(3):240-8. PubMed ID: 20416862
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comprehensive behavioral and molecular characterization of a new knock-in mouse model of Huntington's disease: zQ175.
    Menalled LB; Kudwa AE; Miller S; Fitzpatrick J; Watson-Johnson J; Keating N; Ruiz M; Mushlin R; Alosio W; McConnell K; Connor D; Murphy C; Oakeshott S; Kwan M; Beltran J; Ghavami A; Brunner D; Park LC; Ramboz S; Howland D
    PLoS One; 2012; 7(12):e49838. PubMed ID: 23284626
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of group II metabotropic glutamate receptor modulation on ethanol- and sucrose-seeking and consumption in the rat.
    Windisch KA; Czachowski CL
    Alcohol; 2018 Feb; 66():77-85. PubMed ID: 29220747
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of mGluR2 activation on signal transduction pathways and neuronal cell survival.
    Lee HG; Zhu X; Casadesus G; Pallàs M; Camins A; O'Neill MJ; Nakanishi S; Perry G; Smith MA
    Brain Res; 2009 Jan; 1249():244-50. PubMed ID: 19026996
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Glycine release is regulated by metabotropic glutamate receptors sensitive to mGluR2/3 ligands and activated by N-acetylaspartylglutamate (NAAG).
    Romei C; Raiteri M; Raiteri L
    Neuropharmacology; 2013 Mar; 66():311-6. PubMed ID: 22659408
    [TBL] [Abstract][Full Text] [Related]  

  • 38. mGluR5 regulates REST/NRSF signaling through N-cadherin/β-catenin complex in Huntington's disease.
    de Souza JM; Abd-Elrahman KS; Ribeiro FM; Ferguson SSG
    Mol Brain; 2020 Aug; 13(1):118. PubMed ID: 32859226
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Huntington's disease and Group I metabotropic glutamate receptors.
    Ribeiro FM; Pires RG; Ferguson SS
    Mol Neurobiol; 2011 Feb; 43(1):1-11. PubMed ID: 21153060
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of Drp1 hyperactivation reduces neuropathology and behavioral deficits in zQ175 knock-in mouse model of Huntington's disease.
    Zhao Y; Sun X; Qi X
    Biochem Biophys Res Commun; 2018 Dec; 507(1-4):319-323. PubMed ID: 30449600
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.